Posted by Michael Wonder on 05 Oct 2021
FDA’s naming rule for biosimilars has undermined Congress and health care
4 October 2021 - I recently tried to order white blood cell growth factor (pegfilgrastim) biosimilar for one of my patients. For years, prescribing it has been simple, since the only option was the brand name drug, Neulasta brand pegfilgrastim.
But the patent on Neulasta expired in October 2015, and there are now several FDA approved biosimilars on the market: Fulphila (pegfilgrastim-jmdb), Nyvepria (pegfilgrastim-apgf), Udenyca (pegfilgrastim-cbqv) and Ziextenzo (pegfilgrastim-bmez).
